View Future GrowthPing An Biomedical 과거 순이익 실적과거 기준 점검 0/6Ping An Biomedical 의 수입은 연평균 -75.9%의 비율로 감소해 온 반면, Retail Distributors 산업은 연평균 10.4%의 비율로 감소했습니다. 매출은 연평균 9.5%의 비율로 감소해 왔습니다.핵심 정보-75.91%순이익 성장률-75.69%주당순이익(EPS) 성장률Retail Distributors 산업 성장률20.65%매출 성장률-9.51%자기자본이익률-28.36%순이익률-37.57%최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트Reported Earnings • Feb 01Full year 2025 earnings released: CN¥0.69 loss per share (vs CN¥0.071 loss in FY 2024)Full year 2025 results: CN¥0.69 loss per share (further deteriorated from CN¥0.071 loss in FY 2024). Revenue: CN¥34.1m (down 61% from FY 2024). Net loss: CN¥12.8m (loss widened CN¥11.5m from FY 2024).Reported Earnings • Oct 05First half 2025 earnings released: CN¥0.23 loss per share (vs CN¥0.013 profit in 1H 2024)First half 2025 results: CN¥0.23 loss per share (down from CN¥0.013 profit in 1H 2024). Revenue: CN¥18.2m (down 60% from 1H 2024). Net loss: CN¥4.23m (down CN¥4.47m from profit in 1H 2024).모든 업데이트 보기Recent updates공지 • Mar 10Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026, at 09:00 China Standard Time. Location: 7/f, china united plaza, 1002-1008, tai nan west street, cheung sha wan, kowloon Hong KongReported Earnings • Feb 01Full year 2025 earnings released: CN¥0.69 loss per share (vs CN¥0.071 loss in FY 2024)Full year 2025 results: CN¥0.69 loss per share (further deteriorated from CN¥0.071 loss in FY 2024). Revenue: CN¥34.1m (down 61% from FY 2024). Net loss: CN¥12.8m (loss widened CN¥11.5m from FY 2024).공지 • Jan 10Ping An Biomedical Co., Ltd. announced a financing transactionPing An Biomedical Co., Ltd. entered into a Securities Purchase Agreement and announced a private placement January 9, 2026. The transaction involves participation from individual investors Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor.New Risk • Jan 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Minor Risks Market cap is less than US$100m (US$12.7m market cap).New Risk • Nov 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.56m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Market cap is less than US$10m (US$9.56m market cap). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change).Board Change • Nov 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Jifeng Gao is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 05First half 2025 earnings released: CN¥0.23 loss per share (vs CN¥0.013 profit in 1H 2024)First half 2025 results: CN¥0.23 loss per share (down from CN¥0.013 profit in 1H 2024). Revenue: CN¥18.2m (down 60% from 1H 2024). Net loss: CN¥4.23m (down CN¥4.47m from profit in 1H 2024).Buy Or Sell Opportunity • Oct 01Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at US$0.98. The fair value is estimated to be US$1.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Sep 05Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at US$1.08. The fair value is estimated to be US$1.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.Board Change • Aug 12High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Aug 06Now 27% overvaluedThe stock has been flat over the last 90 days, currently trading at US$1.75. The fair value is estimated to be US$1.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.공지 • Jul 18Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million.Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: $6 Discount Per Security: $0.42Board Change • Jul 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.매출 및 비용 세부 내역Ping An Biomedical가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:PASW 매출, 비용 및 순이익 (CNY Millions)날짜매출순이익일반관리비연구개발비30 Sep 2534-1316030 Jun 2547-911031 Mar 2560-66031 Dec 2474-46030 Sep 2488-15030 Jun 249205031 Mar 249614031 Dec 238904030 Sep 2383-14030 Jun 239713031 Mar 2311143031 Dec 2211363030 Sep 2211573030 Jun 2210755031 Mar 229936031 Dec 219946030 Sep 2110056030 Sep 2055260양질의 수익: PASW 은(는) 현재 수익성이 없습니다.이익 마진 증가: PASW는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PASW은 수익성이 없으며 지난 5년 동안 손실이 연평균 75.9% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PASW의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PASW은 수익성이 없어 지난 해 수익 성장률을 Retail Distributors 업계(-19%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PASW는 현재 수익성이 없으므로 자본 수익률이 음수(-28.36%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YRetail 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/11 11:31종가2026/05/11 00:00수익2025/09/30연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ping An Biomedical Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Feb 01Full year 2025 earnings released: CN¥0.69 loss per share (vs CN¥0.071 loss in FY 2024)Full year 2025 results: CN¥0.69 loss per share (further deteriorated from CN¥0.071 loss in FY 2024). Revenue: CN¥34.1m (down 61% from FY 2024). Net loss: CN¥12.8m (loss widened CN¥11.5m from FY 2024).
Reported Earnings • Oct 05First half 2025 earnings released: CN¥0.23 loss per share (vs CN¥0.013 profit in 1H 2024)First half 2025 results: CN¥0.23 loss per share (down from CN¥0.013 profit in 1H 2024). Revenue: CN¥18.2m (down 60% from 1H 2024). Net loss: CN¥4.23m (down CN¥4.47m from profit in 1H 2024).
공지 • Mar 10Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026, at 09:00 China Standard Time. Location: 7/f, china united plaza, 1002-1008, tai nan west street, cheung sha wan, kowloon Hong Kong
Reported Earnings • Feb 01Full year 2025 earnings released: CN¥0.69 loss per share (vs CN¥0.071 loss in FY 2024)Full year 2025 results: CN¥0.69 loss per share (further deteriorated from CN¥0.071 loss in FY 2024). Revenue: CN¥34.1m (down 61% from FY 2024). Net loss: CN¥12.8m (loss widened CN¥11.5m from FY 2024).
공지 • Jan 10Ping An Biomedical Co., Ltd. announced a financing transactionPing An Biomedical Co., Ltd. entered into a Securities Purchase Agreement and announced a private placement January 9, 2026. The transaction involves participation from individual investors Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor.
New Risk • Jan 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Minor Risks Market cap is less than US$100m (US$12.7m market cap).
New Risk • Nov 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.56m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Market cap is less than US$10m (US$9.56m market cap). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change).
Board Change • Nov 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Jifeng Gao is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 05First half 2025 earnings released: CN¥0.23 loss per share (vs CN¥0.013 profit in 1H 2024)First half 2025 results: CN¥0.23 loss per share (down from CN¥0.013 profit in 1H 2024). Revenue: CN¥18.2m (down 60% from 1H 2024). Net loss: CN¥4.23m (down CN¥4.47m from profit in 1H 2024).
Buy Or Sell Opportunity • Oct 01Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at US$0.98. The fair value is estimated to be US$1.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Sep 05Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at US$1.08. The fair value is estimated to be US$1.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.
Board Change • Aug 12High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Aug 06Now 27% overvaluedThe stock has been flat over the last 90 days, currently trading at US$1.75. The fair value is estimated to be US$1.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.
공지 • Jul 18Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million.Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: $6 Discount Per Security: $0.42
Board Change • Jul 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.